All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Page last updated:
5 March 2020
The information below is based on the European Association of Urology Guideline for Chronic Pelvic Pain (2019).
Self-care advice:
Chronic Pelvic Pain Syndrome (CPPS) is characterized by at least 3 months of pain in the perineum or pelvic floor, often associated with lower urinary tract symptoms, and sexual dysfunction (erectile dysfunction, painful ejaculation, or postcoital pelvic discomfort).
CPPS is the occurrence of chronic pelvic pain when there is no proven infection or other obvious local pathology that may account for the pain.
For over 90% of men with chronic pelvic pain syndrome there is no proven bacterial infection.
A diagnosis is made based on the man's history, physical examination, and the exclusion of other conditions. Before considering antibiotic treatment for CPPS, exclude (or treat) the following other conditions that may be causing symptoms, such as:
Consider a referral to specialist if there is diagnostic uncertainty, or if symptoms are severe.
If all other causes have been excluded, consider antibiotic treatment (see below).
When considering antibiotics (see specifics below), take account of severity of symptoms, risk of complications or having treatment failure (particularly after medical procedures such as prostate biopsy), previous urine culture and susceptibility results, and previous antibiotic use which may have led to resistant bacteria.
Reassess at any time if symptoms worsen rapidly or significantly, taking account of:
Patients can be advised to continue self-care options during antibiotic treatment
Consider referral to specialist if symptoms are not resolved after a course of antibiotics (see local referral guideline)
OR
See sections: 5.1.3 Tetracyclines, 5.1.5 Macrolides, and 5.1.8 Sulfonamides and trimethoprim